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uring the past two decades, anatomical sub-
strates associated with the neuropathology of mood dis-
orders have been revealed through both in vivo neuro-
imaging studies and morphological and neurochemical
studies on postmortem brain tissue.While neuroimaging
studies have given significant insight into the gross mor-
phological location of dysfunctional brain regions in
depression,the neurochemical,cellular,and molecular
features of depression are being unlocked by studies in
postmortem brain tissue.
Novel studies at the microscopic level are establishing
that the mood disorders are associated with abnormali-
ties in cell morphology and distribution,in addition to the
long-recognized neurochemical abnormalities. Major
depressive disorder (MDD) and bipolar disorder (BPD)
have been examined in postmortem brain tissue by sev-
eral laboratories in the past 6 years.Cell-counting stud-
ies report changes in the density and size of both neurons
and glia in a number of frontolimbic brain regions,
including dorsolateral prefrontal,orbitofrontal,and ante-
rior cingulate cortex,and the amygdala and hippocam-
pus.These studies in postmortem brain tissue confirm
and extend structural and functional neuroimaging stud-
ies that reveal volumetric and metabolic changes in the
same frontolimbic brain regions in the same disorders.
Convergence of cellular changes at the microscopic level
with neuroimaging changes detected in vivo provides a
compelling integration of clinical and basic research for
disentangling the pathophysiology of depression.
Regionally localized and cell type–specific changes in
neuronal and glial cytoarchitecture recently identified in
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During the past two decades, in vivo neuroimaging stud-
ies have permitted significant insights into the general
location of dysfunctional brain regions in depression. In
parallel and often intersecting ways, neuroanatomical,
pharmacological, and biochemical studies of postmortem
brain tissue are permitting new insights into the patho-
physiology of depression. In addition to long-recognized
neurochemical abnormalities in depression, novel studies
at the microscopic level support the contention that mood
disorders are associated with abnormalities in cell mor-
phology and distribution. In the past 6 years, cell-counting
studies have identified changes in the density and size of
both neurons and glia in a number of frontolimbic brain
regions, including dorsolateral prefrontal, orbitofrontal,
and anterior cingulate cortex, and the amygdala and hip-
pocampus. Convergence of cellular changes at the micro-
scopic level with neuroimaging changes detected in vivo
provides a compelling integration of clinical and basic
research for disentangling the pathophysiology of depres-
sion. The ultimate integration of these two research
approaches will occur with premortem longitudinal clini-
cal studies on well-characterized patients linked to post-
mortem studies of the same subjects.  
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dysfunction within the monoaminergic, glutamatergic,
and γ-aminobutyric acid (GABA) neurotransmitter sys-
tems in these disorders.
While MDD and BPD are clearly not neurodegenerative
disorders, impaired neuroplasticity is associated with
these mood disorders.
The etiology of histopathological changes observed in
postmortem brain tissue is unknown.It is not clear how
factors such as genetic risk factors,neurodevelopmental
abnormalities,the progression of the disease,or exposure
to antidepressant or mood-stabilizing medications con-
tribute to the abnormal neuronal and glial observations in
mood disorders.It remains to be determined whether the
chronic administration of clinically effective therapeutic
medications can reverse or even staunch histopathologi-
cal changes in the mood disorders.
Alterations in neurons and glia 
in cerebral cortex
In MDD and BPD,reductions in neuronal density and
size in some populations of cortical neurons have been
independently reported.
1-12 These abnormalities have
been described in association cortices such as dorsolat-
eral prefrontal,orbitofrontal,and anterior cingulate cor-
tex,but not in the primary sensory cortical regions such
as somatosensory
1 or visual cortex.
2 Thus, neuronal
abnormalities at the microscopic level in mood disorders
appear to be specific to frontolimbic cortical regions—
observations in postmortem tissue that are consistent
with in vivo neuroimaging studies of volumetric and
metabolic alterations in the same frontocortical regions.
Neuronal abnormalities in mood disorders are not imme-
diately evident,inasmuch as there is no significant reduc-
tion in the density of Nissl-stained neurons measured
across all cortical laminae.
1,3,4 However,when neurons are
assessed within individual cortical layers or in subgroups
determined by size or immunohistochemistry, marked
reductions in neuron density are found in both MDD and
BPD.For example,the density of large-sized neuronal cell
bodies is reduced in cortical layers II to VI in the dorso-
lateral prefrontal and rostral orbitofrontal cortex in MDD.
5
These reductions in density of large-sized neuronal cell
bodies are accompanied by increases in the density of neu-
rons with smaller-sized cell bodies (Figure 1).The con-
comitant decrease in the density of large neuronal cell
bodies and increase in the density of small neuronal cell
bodies suggests that neuronal shrinkage/enlargement or
perhaps altered neuronal development,rather than out-
right neuronal loss,is responsible for neuronal abnormal-
ities in mood disorders.
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Selected abbreviations and acronyms
AVP arginine-vasopressin
BDNF brain-derived neurotrophic factor
BPD bipolar disorder
CRH corticotropin-releasing hormone
GABA  -aminobutyric acid
GFAP glial fibrillary acidic protein
HPA hypothalamic-pituitary-adrenal (axis)
MDD major depressive disorder
NAA N-acetylaspartate
NMDA N-methyl-D-aspartate
Figure 1. Changes in neuronal size and size-dependent density in layer
II of rostral orbitofrontal cortex in a 73-year-old female with
MDD as compared to a 71-year-old psychiatrically normal
female control subject. For both subjects, the postmortem
delay was less than 17 hours and fixation time was less than
10 months. Photomicrograph depicting cell composition across
the six cortical layers in rostral orbitofrontal cortex (upper left).
Expanded printouts of cortical layers with neuronal cell bodies
represented by equivalent diameter circles with the area mea-
sured for the individual neuron in its equatorial plane (right
panel). Note that neuronal sizes are smaller in layers II and III in
the depressed subject than in the control subject. Note espe-
cially dramatic increases in the density of small neurons in layer
II associated with significant reductions in the density of the
largest neurons of this layer. 
Reprinted from reference 5: Rajkowska G, Miguel-Hidalgo JJ, Wei J, et
al. Morphometric evidence for neuronal and glial prefrontal cell pathol-
ogy in major depression. Biol Psychiatry. 1999;45:1085-1098. Copyright
© 1999, Elsevier.
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DepressedIn BPD,decreases in laminar neuronal densities have also
been reported in the dorsolateral prefrontal cortex
4 and
anterior cingulate cortex,
2,6,7 but not by all studies.
1,8
Moreover,in BPD,a decrease in density of pyramidal neu-
rons in cortical layers III and V
4 and nonpyramidal neu-
rons in layer II
6 has been observed in the same cortical
regions.This last observation coincides with reports on
reductions in the density of layer II nonpyramidal neurons
that are identified with an antibody against the calcium-
binding protein,calbindin,in the anterior cingulate cortex
7
and dorsolateral prefrontal cortex
9 in BPD. Calbindin
immunoreactive neurons are known to colocalize GABA.
Our recent measurements of the density and size of cal-
bindin-immunoreactive neurons in layer II and the upper
part of layer III of the dorsolateral prefrontal cortex
revealed a 43% reduction in the density of these neurons
in MDD as compared to controls.
10The depression-related
decrease in calbindin immunoreactive neurons, which
colocalize GABA,may be closely related to in vivo clini-
cal evidence suggesting that MDD is associated with
decreased levels of GABA in cerebral cortex.
11
Another manifestation of neuronal pathology in cerebral
cortex in mood disorders is the reduced size of neuronal
cell bodies. Smaller soma sizes have been reported in
subjects with MDD,as compared to normal controls,in
the dorsolateral prefrontal cortex,
3,5 orbitofrontal cortex,
5
and anterior cingulate cortex.
8,12Two other studies,how-
ever,did not report significant changes in neuronal size
in the anterior cingulate cortex.
1,2 In a manner more sub-
tle than in MDD,reductions in neuronal soma size have
been observed in BPD by some,
4,12 but not by all inves-
tigators.
1,2,8 In another study,a minor increase in the size
of small nonpyramidal neurons was noted in the anterior
cingulate cortex in BPD subjects.
6
Factors leading to a reduction in the size of neuronal
soma are not known.Smaller soma size may be related
to smaller dendritic trees and/or abnormal morphology
of synaptic contacts.However,visualization of neuronal
dendritic trees in cerebral cortex using the Golgi silver
impregnation method has not yet been conducted in sub-
jects with mood disorders. Studies looking at synaptic
proteins in the anterior prefrontal
13 and anterior cingu-
late cortex
14 describe reductions
14 or no changes
13 in
synaptic proteins in mood disorders.Systematic studies
of dendritic trees and synaptic contacts in prefrontal and
cingulate areas are warranted to shed light on the pos-
sible etiology of smaller neuronal cell bodies in mood dis-
orders.
The most consistent cell abnormality described in mood
disorders has unexpected finding of prominent reductions
in the density and number of glial cells.Glial reductions
have been reported consistently by independent labora-
tories in the anterior cingulate cortex,dorsolateral pre-
frontal cortex,and orbitofrontal cortex in MDD and/or
BPD subjects.For example,a 24% to 41% reduction in the
number of a general population of Nissl-stained glial cells
is reported in the subgenual region of the anterior cingu-
late cortex (ventral part of Brodmann’s area 24) in a small
subgroup of patients with familial MDD and familial BPD,
as compared to control subjects.
1 However, when data
from familial and nonfamilial subgroups of patients were
combined,the reductions are not found.The estimation of
glial cell number in this study is combined across all six
cortical layers,and no information is provided on laminar
specificity of glial loss.
Reductions in glial cell density,however,are reported in
specific cortical layers of the anterior cingulate and pre-
frontal cortices in four other studies.These glial reduc-
tions are observed in layer VI of the supragenual ante-
rior cingulate cortex,
8 layers III and V of the dorsolateral
prefrontal cortex
3-5 and in layers III,IV,V,and VI of the
caudal orbitofrontal cortex,
5 in mood disorder patients.
Glial cell size and shape,in addition to density,appears to
be affected in mood disorders.The size of glial cell bodies
(corresponding to glial cell nuclei in Nissl-stained mater-
ial) has been estimated in several studies.In three of these
investigations,glial size is reported as increased,
3-5 whereas
two other studies find glial size to be unchanged in MDD
or BPD.
1,15 Significant increases in glial size are observed
in the dorsolateral prefrontal cortex in BPD
4 and to a
smaller degree in MDD,
5 comparing these cohorts to psy-
chiatrically normal control subjects.More recently,similar
increases in glial size are noted in the anterior cingulate
cortex in MDD.
12 In addition,changes in the shape of glial
nuclei to a less rounded conformation are detected in the
dorsolateral prefrontal cortex in BPD.
4 Reductions in glial
density,paralleled by an increase in the size of glial nuclei,
suggest that some compensatory mechanisms may take
place in mood disorders. It can be speculated that a
decrease in the density of glial cells is indicative of a
decrease in the number of normally functioning glial cells.
At the same time,glial cells that survive and are not dam-
aged might be forced to play a larger role in supporting the
metabolic needs of the surrounding neurons.As a conse-
quence of increased metabolic demand,the nuclei of these
glial cells might enlarge in size and change in shape.
Postmortem abnormalities in depression - Stockmeier and Rajkowska Dialogues in Clinical Neuroscience - Vol 6 . No.2 . 2004
187Glutamate-induced swelling of astroglia,reported in ani-
mal cell cultures,
16 may be another factor in the etiology of
enlarged glial cells in depression.
Glial cell pathology in mood disorders does not appear
to be universally noted throughout the cerebral cortex.
Changes in glial cell density or number are not found in
the sensorimotor cortex in either MDD or BPD.
1 Recent
reports suggest a lack of marked glial pathology in the
supragenual part of the anterior cingulate cortex,
12 the
entorhinal cortex in BPD and MDD,
17 or the most rostral
part of the orbitofrontal cortex in MDD (corresponding
to the transitional cortex between Brodmann areas 10
and 47).
5
Glial pathology in mood disorders has yet to be systemat-
ically studied in subcortical structures. Only one report
suggests that glial pathology extends to limbic subcortical
regions,with a significant reduction in glial number noted
in the amygdala in subjects with MDD and unmedicated
subjects with BPD.
17
Alterations in neurons and glia 
in the hippocampus
Preclinical and neuroimaging studies have implicated the
hippocampal formation in the pathophysiology of MDD.
In addition,plasticity within the hippocampal formation
may be involved in neurobiological responses to stress and
to antidepressant drug action.
18 Evidence for an interac-
tion between the hippocampus and depression comes
from magnetic resonance imaging (MRI) studies examin-
ing the volume of the hippocampus. Studies using MRI
demonstrate reduced volume of the hippocampus in sub-
jects with MDD or a history of MDD,
19-26 but not in other
studies.
27-29 It appears that hippocampal atrophy is prefer-
entially seen in older, recurrently depressed subjects or
subjects who are refractory to antidepressant medications.
Recently,hippocampal volume and function was assessed
over the course of illness in younger patients with MDD.
26
Recollection memory is diminished in subjects with 
either a first episode or multiple episodes of depression.
However,hippocampal volume is generally considered to
be significantly decreased only in older depressed subjects
with multiple episodes of depression.
25,26
Few studies have structurally examined the postmortem
human hippocampus in depression.Cellular integrity and
apoptosis have been examined in the hippocampus in sub-
jects with depression,steroid-treated subjects,and normal
control subjects.
30,31 Using semiquantitative methods,these
studies report no significant cell loss in any hippocampal
region in any of the subject groups.In most of the depres-
sives, there was evidence for a slight increase in frag-
mented DNA associated with apoptosis and necrotic neu-
ron death detected in the dentate gyrus,CA1 and CA4.
30
Decreases in astrocytic immunoreactivity for cellular
GFAP and the neuron-specific phosphoprotein B50 (or
GAP-45) were detected in CA1 and CA2 in depression.
31
The authors suggest that apoptosis may only be a minor
contributor to volume changes in the hippocampus in
depression, while patterns of reactive astrogliosis and
synaptic reorganization proteins are significantly altered
in only some hippocampal regions in depression.Other
reports of hippocampal changes in mood disorders iden-
tify a significant decrease in the density of nonpyramidal
neurons in the CA2 region and a reduction in reelin-pos-
itive cell density in the hilus in subjects with BPD.
32,33Two
other studies conducted on the postmortem hippocampal
formation in a small sample of subjects with BPD reveal a
decrease in the density and size of nonpyramidal neurons
in the CA2 region and some disorganization in neuronal
clusters in layers II and III of the entorhinal cortex.
34,35
Neuronal and glial cell packing density and soma size were
estimated recently in Nissl-stained sections including the
hippocampal subfields in 16 subjects with MDD and 16
age-matched normal control subjects.
36 Representative
photomicrographs are presented in Figure 2.Prominent
abnormalities in the CA regions and dentate gyrus are
found in subjects with MDD.There is a significant increase
in the mean density of pyramidal neurons in depressed
subjects,as compared with normal control subjects.In the
granule cell layer of the dentate gyrus,cell density is sig-
nificantly increased in MDD.In addition,there is a signif-
icant decrease in the mean soma size of pyramidal neurons
in depressed subjects,as compared with normal control
subjects.On the basis of covariate analyses,the main find-
ings of increased neuronal density and decreased neuron
soma size in depression are not significantly altered when
taking into consideration such factors as gender,age,post-
mortem interval,tissue pH,brain weight,smoking,anti-
depressant drug prescription in the last month of life,or
suicide.The substantial increases noted in neuronal pack-
ing density and decrease in neuronal soma size detected
in postmortem tissue may be related to the decrease in
hippocampal volume noted by some in MDD.
Glial pathology in depression appears to extend beyond
the frontal cortex to the hippocampus.A recent study of
the hippocampus in a large number of subjects with MDD
Clinical research
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nificant increase in the density of glial cells in all hip-
pocampal CA subfields and the granule cell layer of the
dentate gyrus.
36 In MDD,increases in the packing density
of glial cells detected in postmortem tissue suggests a
potential reduction in surrounding neuropil (see above),
and may be related to decreases in hippocampal volume
noted by neuroimaging studies in MDD (see above).
The different pattern of density change noted in depres-
sion in the hippocampus in contrast to frontal cortical
areas may be related to a unique reduction in neuropil in
the hippocampus in depression.Neuropil consists of the
lattice of glial cells and their processes,dendrites,and prox-
imal axons surrounding neuron cell bodies.The hypothe-
sis of neuropil reduction in the hippocampus in MDD is
supported by other postmortem studies revealing a
decrease in dendritic spine density on neurons and dimin-
ished arborization of apical dendrites in the subiculum in
a small group of mixed subjects with bipolar disorder or
depression
37 and decreased levels of synaptic proteins
found in CA4 in BPD.
38Thus,the diminished volume of
the hippocampus noted by some in depression may be crit-
ically determined by a loss in neuropil including dendritic
branching,dendritic spine complexity,and glial processes.
The expression of brain-derived neurotrophic factor
(BDNF) has been measured in the hippocampus of sub-
jects with depression,and alterations in these factors might
be related to changes in cell density and volume in depres-
sion. There is preliminary evidence that BDNF in the
human hippocampus may be regulated by chronic treat-
ment with antidepressant medications.In an immunohis-
tochemical study of subjects with MDD and others with
BPD or schizophrenia,the immunoreactivity of BDNF,as
measured by optical density,is upregulated in the dentate
gyrus and hilus only in subjects taking antidepressant med-
ications (regardless of psychiatric diagnosis).
39 Chen et al
39
provide the first evidence beyond rodent studies that
chronic antidepressant drugs upregulate the expression of
BDNF in the human hippocampus. In a recent study,
Dwivedi et al
40 observed a significant reduction in mRNA
and protein levels of BDNF in hippocampus as well as
dorsolateral prefrontal cortex in suicide victims with either
MDD or other psychiatric disorders.In the Dwivedi et al
40
study, the decrease in expression of BDNF occurred
regardless of antidepressant treatment.It remains to be
determined whether alterations in BDNF are related to
increases in the packing density of neurons in the hip-
pocampal formation or prefrontal cortex.
The different pattern of neuronal pathology in the frontal
cortex (decrease in density) and hippocampus (increase in
density) suggests unique involvement of these brain
regions in the neuropathology of depression.Other evi-
dence of dissimilarities between prefrontal cortex and hip-
pocampus has been reported in MDD.
41-43 Successful clini-
cal treatment (or even the use of placebo) in depression
was associated with an increase in metabolism in prefrontal
cortex and a decrease in metabolism in hippocampus.
Alterations in neurons and glia 
in subcortical structures
The search for morphological abnormalities in subjects
with mood disorders has been less intense in subcortical
structures than in cerebral cortical regions.Only a few
studies in postmortem brain tissue on a relatively small
number of subjects have attempted to estimate the num-
ber of neurons in such subcortical structures as hypo-
thalamus,dorsal raphe nucleus,locus ceruleus,and amyg-
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Figure 2. Brightfield photomicrographs of coronal sections of the post-
mortem human hippocampal formation. A. Cresyl violet–stained
coronal section from a 54-year-old male (23-h postmortem inter-
val). B. An adjacent coronal section processed by Timm staining.
Note the intensely stained granule cell layer of the dentate gyrus
(DGgr) in A and B, and the clear demarcation in B between hip-
pocampal subfields CA2 and CA3 afforded by the Timm stain-
ing. Pyramidal neurons and glial nuclei of CA3 are highlighted
in C by the large white arrows and white arrowheads, respec-
tively. Neurons and glial nuclei of the granule cell layer of the
dentate gyrus are depicted in D by the large black arrows and
black arrowheads, respectively. The scale bars in A and C are 750
µm and 25 µm, respectively. dala.
44-52 Results of these subcortical histopathological
studies are somewhat inconsistent.Increases,decreases,
or no change in the cell number or density are reported
in the hypothalamus and brain stem nuclei in depressed
subjects.
Stereological investigation of specific types of hypothal-
amic neurons reveals an increase in the numbers of argi-
nine-vasopressin (AVP)–immunoreactive neurons,oxy-
tocin-expressing neurons, and corticotropin-releasing
hormone (CRH) neurons in the paraventricular nucleus
in subjects with BPD or MDD,compared to normal con-
trols.
44,45 Moreover,increases in CRH mRNA,and in the
number of CRH neurons colocalizing AVP are also
found in depressed patients.
46,47 These findings of
increases in specific immunoreactive neurons are consis-
tent with the evidence of activation of the hypothalamic-
pituitary-adrenal (HPA) axis in some subsets of
depressed patients.
48 On the other hand,decreased num-
ber and density of nitric oxide synthase–containing neu-
rons in the paraventricular hypothalamic nucleus are
described in a small group of subjects with either MDD
or BPD.
49
Subtle structural abnormalities have been reported in
mood disorders in the monoaminergic brain stem nuclei,
the major sources of serotonin (dorsal raphe nucleus)
and norepinephrine (locus ceruleus) projections to the
cerebral cortex. An increased number and density of
tryptophan hydroxylase immunoreactive neurons is
observed in the dorsal raphe nucleus of suicide victims
with MDD compared with controls.
50 In suicide victims,
Arango et al
51 report fewer pigmented neurons within
the rostral locus ceruleus.Another study in a larger num-
ber of subjects found no differences in the number of
pigmented neurons in the locus ceruleus between sub-
jects with MDD (most were suicides) and control sub-
jects.
52 Although the number of neurons in the locus
ceruleus does not appear altered in MDD, CRH
immunoreactivity is increased in the locus ceruleus and
pontine dorsal and median raphe nuclei.
53,54 No changes
in neuronal densities were detected in amygdala in sub-
jects with either MDD or BPD, as compared to normal
controls.
17
These postmortem findings suggest that some changes in
the morphology of hypothalamic neurons and brain stem
neurons may take place in mood disorders. However,
future studies employing stereological techniques and a
larger number of subjects are required to determine the
exact pathology in these regions in depression.
Functional implications of pathological
changes in neural circuits
Morphological abnormalities detected postmortem in
mood disorders are most likely related to dysfunction of
neural circuits regulating emotional, cognitive, and
somatic symptoms exhibited by subjects with MDD or
BPD. In fact, alterations in neuronal density and size
have been found in the dorsolateral prefrontal,
orbitofrontal,and anterior cingulate cortex,the neurons
of which give rise to the frontal circuits critical for higher
cognitive and limbic functioning.
55 Subtle neuronal alter-
ations are also reported in the hypothalamus and hip-
pocampus,further evidence of dysfunction in limbic cir-
cuits in depression.
Some of the cellular abnormalities detected postmortem
in cortical and subcortical structures in MDD and BPD
may be related to disruption of monoaminergic trans-
mission in depression.Studies in postmortem brain tis-
sue identify alterations in serotonin and norepinephrine
receptors and transporters in the dorsolateral prefrontal
cortex and ventrolateral/orbitofrontal cortex in brains
from suicide victims with or without clinical depression.
56
These cortical regions also exhibit abnormal cell density
and size in cell-counting studies of postmortem tissue.For
example,cellular changes found in superficial layers of
the prefrontal cortex in depressed subjects may be
related to alterations in serotonin-1A receptors in super-
ficial layers of cortex in suicide victims.
57 In a neu-
roimaging study,the authors find that radioligand bind-
ing to serotonin-1A receptors is decreased in
medication-free subjects with MDD in several cortical
regions,including medial temporal cortex,the temporal
pole,orbitofrontal cortex,anterior cingulate cortex,insula
and dorsolateral prefrontal cortex.
58 Expression of
another component of serotonin neurotransmission,the
serotonin transporter,is also decreased in the dorsolat-
eral prefrontal and ventral/orbitofrontal cortex in post-
mortem brains from depressed suicide victims.
59,60
Detailed laminar analysis of the density of serotonin
transporter–immunoreactive axons reveals that this
deficit in depression is localized in cortical layer VI of the
dorsolateral prefrontal cortex.
59 The serotonin-trans-
porter deficit may be related to the pathology of layer VI
neurons reported in the same cortical layer by post-
mortem cell-counting studies in depression.
Moreover, subtle neuronal abnormalities reported by
some studies in the monoaminergic brain stem nuclei
Clinical research
190suggest dysfunction of monoaminergic projections orig-
inating from the brain stem neurons and terminating in
frontolimbic cortical regions.It is likely that the functions
and morphology of cortical neurons are affected by alter-
ations in the functional state of noradrenergic,seroton-
ergic, and dopaminergic neurons that project axons to
prefrontal and anterior cingulate cortex. Postmortem
neurochemical studies in MDD report alterations in
noradrenergic α2-adrenergic receptors and the norepi-
nephrine transporter,as well as levels of tyrosine hydroxyl-
ase in the locus ceruleus,
52,61,62 serotonin-1A receptors in
the midbrain dorsal raphe nucleus,
63 and dopaminergic
receptors and transporters in the amygdala.
64
The layer-specific changes in neuronal density and size
identified in mood disorders implies that both inhibitory
local circuit neurons and excitatory projection types of
cortical neurons may be involved in the neuropathology
of mood disorders. Nonpyramidal inhibitory neurons
using GABA are localized mainly in cortical layer II and
establish local cortico–cortical connections within or
between adjacent functional columns of cortical cells.In
contrast, pyramidal glutamatergic excitatory neurons
reside predominantly in cortical layers III,V,and VI and
give rise to long projections to other cortical associational
regions (layer III), striatum (layer V), and thalamus
(layer VI).
Neuronal pathology detected in cortical layers III,V,and
VI of the dorsolateral prefrontal cortex and anterior 
cingulate cortex in MDD may be associated with the 
pathology of excitatory pyramidal neurons within these 
laminae that use glutamate as their neurotransmitter.
Moreover,the density of pyramidal neurons is selectively
reduced in the dorsolateral prefrontal cortex in subjects
with BPD,
4 further confirming the pathology of gluta-
matergic neurons in mood disorders.These findings in
postmortem brain tissue coincide with an in vivo proton
magnetic resonance spectroscopy study in the anterior
cingulate cortex revealing a reduction in glutamate lev-
els in depression.
65 There is increasing preclinical and
clinical evidence that antidepressant drugs directly or
indirectly reduce the function of N-methyl-D-aspartate
(NMDA) glutamate receptors.
66 Depression-related
decreases in glutamate levels or the density of gluta-
matergic pyramidal neurons may alter in cortex and else-
where the glutamatergic recognition site and its coupling
to the NMDA receptor complex. One study of suicide
victims, some of whom were diagnosed with MDD,
reveals changes in the glutamatergic recognition site and
its coupling to the NMDA receptor complex in the ante-
rior prefrontal cortex.
67 Interestingly,drugs that reduce
glutamatergic activity or glutamate receptor–related sig-
nal transduction may also have antimanic effects.
66
Reductions in size and density of layer II neurons in the
orbitofrontal and dorsolateral prefrontal cortex,as well
as reductions in the density of nonpyramidal neurons in
layer II of the anterior cingulate cortex suggest deficient
GABAergic neurotransmission.Most nonpyramidal neu-
rons in cortical layer II colocalize GABA and recent clin-
ical evidence suggests that MDD is associated with
decreased levels of cortical GABA.
11
In summary, the localization of morphological abnor-
malities in the mood disorders occurs in prefrontolimbic
circuits that are likely to regulate emotional,cognitive,
and somatic symptoms in depression.The observation in
the mood disorders of neuronal pathology in specific cor-
tical layers gives support to the hypotheses that the
monoamine, glutamate, and GABA neurotransmitter
systems are involved in the pathophysiology of these dis-
orders.It remains to be determined whether the cellular
pathology is the reason for, or the consequence of,
depression.
Functional implications of glial 
abnormalities in depression
The glial cells analyzed in the above studies do not rep-
resent a homogeneous population of cells.Glial cells are
composed of distinct populations of oligodendrocytes,
microglia, and astrocytes. The crucial role of glial cell
types in brain function is currently being reevaluated.In
addition to their traditional roles in neuronal migration
(radial glia),myelin formation (oligodendrocytes),and
inflammatory processes (astrocytes and microglia),glia
(predominantly astrocytes) are now thought to provide
trophic support to neurons,neuronal metabolism,and the
formation of synapses and neurotransmission.
15
The three distinct glial cell types cannot be identified in
the previously mentioned studies as those tissues were
stained for Nissl substance and such staining does not dis-
tinguish reliably between types of glial cells.Nissl staining
only reveals morphological features of glial cell bodies and
not glial cell processes.On the other hand,recent immuno-
histochemical examination of glial fibrillary acidic protein
(GFAP),a marker of reactive astroglia,in the dorsolateral
prefrontal cortex implicates astrocytes in the overall glial
pathology in MDD.
68Although no significant group dif-
Postmortem abnormalities in depression - Stockmeier and Rajkowska Dialogues in Clinical Neuroscience - Vol 6 . No.2 . 2004
191ferences in the packing density of GFAP-reactive astro-
cytes are present in this study,there is a significant corre-
lation between age and GFAP immunoreactivity among
subjects with MDD, when the entire group of MDD
(young and old) is compared with normal controls.A sig-
nificant reduction in the population of reactive astroglia is
found in a small subgroup of young (30 to 45 years old)
subjects with MDD,as compared to young control subjects
and older (46 to 86 years old) subjects with MDD (Figures
3A and 3B).This subgroup of younger adults with MDD
also had a shorter duration of depression and most of
these subjects were suicide victims.Recent observations
from our laboratory confirm that the levels of GFAP pro-
tein are also reduced in these young adults with MDD as
compared to age-matched control subjects (Figures 3C
and 3D),and that GFAP levels are positively correlated
with age at the time of death and with the age of onset of
depression.
69Thus,the involvement of GFAP expression
in early- versus late-life depression differs because the
underlying pathophysiology in early-life depression is dif-
ferent from that in late-life depression.Clinical evidence
confirms that late-onset depression (first depressive
episode when older than 50 years) differs from early-onset
depression by its etiology, phenomenology, and cere-
brovascular pathology.
70-72
Alterations in GFAP in both BPD and MDD are also
suggested by a proteomic study in which different forms
of GFAP proteins displayed disease-specific abnormali-
ties.
73 Oligodendrocytes may also be involved in the cel-
lular pathology of depression.In both the dorsolateral
prefrontal and anterior frontal cortex in subjects with
BPD or MDD,there are ultrastructural changes in oligo-
dendrocytes and there is a reduction in the density and
immunoreactivity of these cells.
74,75 Moreover,key oligo-
dendrocyte-related and myelin-related gene expression
is reduced in the dorsolateral prefrontal cortex in BPD.
76
While these results are intriguing,further immunohisto-
chemical and molecular studies are needed to definitively
determine which specific glial cell types are compromised
in BPD and whether the same or different types of glial
cells are involved in the pathology reported in MDD.
Reductions in glial number and density, in addition to
changes in size and shape, might be related to the dys-
function of monoamine and glutamate systems reported
extensively in depression.For example,astrocytes express
virtually all of the receptor systems, ion channels, and
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Figure 3. An illustration of the pathology of glial cells found in the dorsolateral prefrontal cortex in MDD.
5,68 Reductions in the glial fibrillary acidic pro-
tein (GFAP) immunoreactive astroglia are found in a subgroup of young adults with major depression as compared to aged-matched control
subjects and older subjects with major depression (A) and these reductions are correlated with the age of the subjects at the time of death
(B). Recent preliminary observations (Si et al, unpublished observation) indicate that the levels of GFAP protein in the same area of the dor-
solateral prefrontal cortex are also reduced in these young (D) but not old (C) subjects with major depression as compared to age-matched
control subjects. Note that the level of actin, another protein in brain, is unchanged in a depressed subject as compared to the control.  
Reproduced (A and B) from reference 68: Miguel-Hidalgo JJ, Baucom C, Dilley G, et al. Glial fibrillary acidic protein immunoreactivity in the prefrontal cortex
distinguishes younger from older adults in major depressive disorder. Biol Psychiatry. 2000;48:861-873. Copyright © 2000, Elsevier.
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Dtransporters found in neurons.
15 Thus, the postsynaptic
monoaminergic receptors distributed on glial cell bodies
and processes may play a role in serotonin,norepineph-
rine,or dopamine neurotransmission.Moreover,astroglia
are the primary sites of glutamate uptake by glial trans-
porters and are important in regulating NMDA receptor
activity.Astroglia regulate the levels of extracellular glu-
tamate and thereby protect neurons in vitro from cell
death and provide energy for neurons.Astrocytic pathol-
ogy in MDD may indirectly promote glutamate-mediated
neuronal excitotoxicity, with consequences that may be
detected by functional neuroimaging.
A mounting body of data suggests that treatment with
antidepressant or mood-stabilizing medications regulates
neuronal survival and also influences neurogenesis.
Pharmacologically induced increases in neurogenesis in
adult rodent brain have been reported in two indepen-
dent studies.
77,78 Moreover,there is evidence that treat-
ment with lithium induces an increase in the astrocytic
protein GFAP in rodent hippocampus
79,80 and the neural
lobe of the pituitary.
81 However,whether these increases
represent a protective or compensatory effect of these
medications,and the mechanisms underlying the regula-
tion of neurogenesis and glial proliferation have to be
further investigated.Furthermore,a precise link between
cell loss and atrophy,observed in the postmortem human
brain,and medication-induced production of new cells,
observed in the animal brain,has yet to be established.
Limitations in postmortem pathology 
studies in mood disorders
Postmortem studies cannot yet clearly define whether a
true loss of cells underlies prominent reductions in cell
density and size detected in mood disorders.For the esti-
mation of a total number of neurons or glia in a particular
brain region,it is essential that the total volume of a stud-
ied area be calculated.To measure the entire volume,the
exact borders of the studied region have to be estab-
lished,
82,83 so that sampling is confined to the region within
these borders.Unfortunately,in most studies of mood dis-
orders in postmortem tissue, limited availability of the
complete tissue region,as well as limitations in reliably dis-
tinguishing cytoarchitectonic borders of a studied region,
have prevented the estimation of a total tissue volume
and,consequently,total cell number. In one study where
the total cell number was estimated in the subgenual cor-
tex,a loss of glial but not neuronal cells has been demon-
strated in familial mood disorders.
1 Glial reductions
reported in this study may in fact reflect a true loss of glial
cells since the neuroimaging studies in the same cortical
region show a reduction in the volume of gray matter.
84
There are unquestionable limitations to the use of post-
mortem brain tissue in studying the mood disorders.
56
Some of the critical issues to be considered when inter-
preting the studies of postmortem brain tissue include the
psychiatric status of the subject at the time of death and
the underlying psychiatric disorder,whether “control”sub-
jects were psychiatrically normal,the cause of death of the
subjects (suicide or by other means),evolving criteria used
to establish psychiatric diagnoses,the possible inclusion of
subjects with concurrent psychoactive substance use dis-
orders, the regional and hemispheric localization of the
brain regions being studied,and the presence and duration
of treatment with a psychotropic medication.Other fre-
quent drawbacks to studies of postmortem brain tissue
include low numbers of subjects per cohort,or inadequate
expertise in cytoarchitectonic delineation of individual
brain regions.Ideally,longitudinal clinical studies on well-
characterized patients should be linked to subsequent post-
mortem studies of the same subjects.It is important to seek
to control for the potential effects of suicide on post-
mortem biological observations in depression.In two of
our studies,
5,36 enough depressed nonsuicide subjects were
available to tentatively determine that the main findings
of these studies appear to persist regardless of whether the
depressed subjects died by suicide or natural causes.While
suicide makes tissues available for most postmortem stud-
ies of depression,the results obtained with this cohort must
be cautiously interpreted since the majority of living indi-
viduals with depression do not attempt or commit suicide.
In the mood disorders,the alterations in cell density and
size are likely to be related to the disorder itself and not
to the age of subjects at the time of death,postmortem
delay, or the time of fixation of the tissue. Statistical
analyses conducted in all of the above morphometric
studies yielded no significant correlation between cell
density or size and any of these confounding variables.It
cannot be ruled out,however,that some of the cellular
alterations in mood disorders are related to prior treat-
ment with antidepressants and lithium (for further dis-
cussion see reference 85).
The question of whether cell abnormalities can be attrib-
uted to the effect of therapeutic medications is open to
debate. There have been no systematic studies on the
effect of antidepressant and mood-stabilizing medications
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human brain,most likely due to an insufficient number of
treated versus untreated subjects.
Conclusion
Cellular abnormalities in mood disorders are observed
in the dorsolateral prefrontal cortex,anterior cingulate
cortex,orbitofrontal cortex,hippocampus,and amygdala.
In these same brain regions,neuroimaging studies reveal
volumetric,metabolic,and neurochemical alterations in
subjects with mood disorders.
Structural neuroimaging studies in mood disorders pro-
vide evidence of modest but intriguing volumetric changes
that suggest cell loss and/or atrophy.
86 Some studies,but
not all,report enlargement of the lateral and third ventri-
cles in mood disorders
87 that may be indicative of atrophy
of surrounding cortical and subcortical regions.
Functional neuroimaging studies in MDD and BPD lend
further support to physiological abnormalities in cortical
and subcortical frontolimbic regions.Abnormal regula-
tion of glucose metabolism,regional cerebral blood flow,
and high-energy phosphate metabolism are observed in
the prefrontal and temporal cortex, basal ganglia, and
amygdala in mood disorders.
88 Neuroimaging studies that
examine neurochemical changes in the living brain pro-
vide further support for the hypothesis that mood disor-
ders are associated with changes in cell viability and func-
tion. For example, high-resolution magnetic resonance
spectroscopy in unmedicated subjects with BPD report
decreased N-acetylaspartate (NAA) levels bilaterally in
the hippocampus
89 and in the dorsolateral prefrontal cor-
tex,
90 as compared to healthy controls.In contrast,thera-
peutic doses of lithium increase levels of NAA in the
brain of subjects with BPD.
91 Such increases in NAA are
found in a number of regions including frontal cortex,and
are localized almost exclusively in the gray matter.NAA
is regarded as a measure of neuronal viability and func-
tion, and therefore the changes in NAA levels seen in
BPD strongly implicate alterations in neuronal viability,
which may be related to alterations in cell number,cell
density, and size, and related volumetric changes.
Interestingly, recent magnetic resonance spectroscopic
studies of nonhuman primates exposed to early life stres-
sors or repeated stressors also reveal a significant
decrease in NAA. The NAA decrease in the animals
exposed to repeated stressors was normalized by chronic
treatment with the antidepressant tianeptine.
92 Increases
in glutamate-glutamine-GABA metabolites in the adult
anterior cingulate cortex of these animals were also
observed 10 years after the stressors.These NAA mea-
sures reflect neuronal integrity and metabolism whereas
changes in glutamate-glutamine-GABA metabolites may
reflect changes in membrane structure,glial functions,and
glutamate content.Together,the above data suggest that
structural and metabolic alterations observed in vivo may
be related to alterations in cell viability,which,itself,may
be related to alterations in cell number,density,and size
observed in postmortem tissues at the microscopic level.
The studies reviewed above undeniably prove the use-
fulness of postmortem tissue in unraveling the micro-
scopic anatomical substrate of depression.For the first
time,postmortem cell-counting studies in mood disorders
have established that MDD and BPD are brain diseases
with unique pathological alterations in neuronal and glial
cells.The precise region- and layer-specific alterations in
neuronal and glial architecture observed in mood disor-
ders are consistent with the hypotheses of specific dys-
function in monoamine,glutamate,and GABA neuro-
transmitter systems in these disorders. Moreover,
colocalization of cellular changes detected in postmortem
tissues with in vivo neuroimaging findings proves that
postmortem studies provide an important interface
between clinical and basic research in unraveling the
neuroanatomical substrates of depression.
Postmortem studies in depression also indicate that while
MDD and BPD are clearly not neurodegenerative disor-
ders,these disorders are associated with impaired cellular
neuroplasticity and resilience.It remains to be fully eluci-
dated to what extent these findings represent neurodevel-
opmental abnormalities,progression of the disorder,bio-
chemical changes (in glucocorticoid or trophic factors
levels) accompanying repeated disease episodes, or the
results of treatment with therapeutic medications. It is
unknown whether the cellular changes observed post-
mortem in mood disorders can be reversed by antidepres-
sant and mood-stabilizing medications.Although molecu-
lar and genetic mechanisms associated with depression are
yet to be unraveled,preliminary microarray studies of gene
expression in postmortem brain tissues from subjects with
mood disorders confirm that the dorsolateral prefrontal
and anterior cingulate cortex are sites of pathology in
mood disorders.
93,94 ❏
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Alteraciones celulares en la depresión: 
evidencia proveniente de tejido cerebral 
postmortem
Durante los últimos veinte años, los estudios de
neuroimágenes in vivo han permitido un impor-
tante conocimiento acerca de la ubicación general
de regiones cerebrales disfuncionales en la depre-
sión. En paralelo y a menudo intersectándose, los
estudios neuroanatómicos, farmacológicos y bio-
químicos del tejido cerebral postmortem están faci-
litando nuevos conocimientos sobre la fisiopatolo-
gía de la depresión. Además de las alteraciones
neuroquímicas reconocidas desde hace bastante
tiempo, nuevos estudios a nivel microscópico per-
miten sostener que los trastornos afectivos están
asociados con alteraciones en la morfología y en la
distribución celular. En los últimos séis años, estu-
dios de recuento celular han identificado cambios
en la densidad y el tamaño tanto de las neuronas
como de la glía en varias regiones cerebrales fron-
tolímbicas que incluyen las cortezas dorso-lateral
prefrontal, órbito-frontal y cingulada anterior, y la
amígdala y el hipocampo. La convergencia de cam-
bios celulares a nivel microscópico con cambios en
las neuroimágenes detectados in vivo provee una
integración forzada de la investigación clínica y
básica para desentrañar la fisiopatología de la
depresión. La integración definitiva de estas dos
aproximaciones de investigación ocurrirá cuando se
puedan relacionar los estudios clínicos longitudi-
nales premortem en pacientes bien caracterizados
con los estudios postmortem de los mismos sujetos.
Anomalies cellulaires observées dans le 
tissu cérébral post mortem au cours de la
dépression
Ces 20 dernières années, les études de neuro-imagerie in
vivo ont permis des avancées significatives dans la com-
préhension de la localisation générale des régions
cérébrales dysfonctionnelles au cours de la dépression. Les
études neuroanatomiques, pharmacologiques et bio-
chimiques des tissus cérébraux post mortem offrent ainsi,
en parallèle et souvent de façon croisée, un aperçu renou-
velé de la physiopathologie de la dépression. De nouvelles
études au niveau microscopique ont conforté l’hypothèse
selon laquelle les troubles de l’humeur sont associés à des
anomalies de la distribution et de la morphologie cellu-
laires, tout en confirmant l’existence d’anomalies neu-
rochimiques connues depuis longtemps dans la dépression.
Ces 6 dernières années, des études de comptage cellulaire
ont identifié des modifications dans la densité et la taille
des neurones et de la névroglie au niveau d’un certain
nombre de régions cérébrales frontolimbiques comprenant
les cortex dorsolateral préfrontal, orbitofrontal et cingu-
laire antérieur, ainsi qu’au niveau de l’amygdale et de 
l’hippocampe. La convergence entre les modifications cel-
lulaires observées au niveau microscopique et les change-
ments in vivo détectés par neuro-imagerie témoigne avec
éloquence de l’utilité d’associer la recherche clinique et
fondamentale en vue d’élucider la physiopathologie de 
la dépression. L’ultime intégration de ces deux approches
de recherche consistera à rapprocher les données issues
d’études cliniques longitudinales pre mortem sur des
patients bien définis avec celles provenant d’études post
mortem sur ces mêmes patients.
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